The biopharma industry is entering the second half of the year with a spring in its step. After seeing pessimism engulf the sector in 2023, GlobalData found healthcare industry professionals had a sunnier disposition as they assessed their growth prospects in its latest survey.

生物制药行业进入下半年，迎来了春天。在2023年悲观情绪席卷该行业之后，GlobalData在其最新调查中评估其增长前景时发现，医疗保健行业专业人士的性格更为乐观。

Healthcare industry professionals were a cheerful bunch as they began to put the COVID-19 pandemic behind them in 2022 but the situation soured sharply last year. In 2022, GlobalData found 81% of the respondents to its survey were optimistic about the industry’s growth prospects for the next 12 months.

2022年，医疗保健行业的专业人士开始将新型冠状病毒（COVID-19）大流行抛在脑后，他们感到非常高兴，但去年情况急剧恶化。2022年，GlobalData发现81%的受访者对该行业未来12个月的增长前景持乐观态度。

Last year, the figure fell to 47% as inflation, geopolitical problems and more weighed on the industry..

去年，由于通货膨胀、地缘政治问题以及更多因素对该行业造成压力，该数字降至47%。。

The last two surveys suggest 47% was the nadir. GlobalData saw the proportion of people optimistic about growth climb to 60% when it polled the industry six months ago. The outlook was rosier still in the latest survey when 73% of the 124 surveyed healthcare industry professionals said they are optimistic about near-term growth.

最近两次调查显示，47%是最低点。GlobalData在六个月前对该行业进行民意调查时，对增长持乐观态度的人比例攀升至60%。在最新的调查中，前景仍然乐观，124名接受调查的医疗保健行业专业人士中有73%表示他们对近期增长持乐观态度。

Seven percent of people said they are pessimistic, with the rest in the middle..

7%的人表示悲观，其余的人持中间立场。。

Urte Jakimaviciute, senior director of market research and thematic intelligence at GlobalData, set out the reasons for “hope that the industry is on the path of rebounding from the impact of the COVID-19 pandemic and subsequent geopolitical conflicts” in a statement about the survey data.

GlobalData市场研究和主题情报高级主管Urte Jakimaviciute在一份关于调查数据的声明中阐述了“希望该行业正在从新型冠状病毒大流行和随后的地缘政治冲突的影响中反弹”的原因。

Related

相关

The top 20 drugs by worldwide sales in 2023

2023年全球销售额前20种药物

“Despite the ongoing challenges in the geopolitical landscape, there is a gradual decline in inflation, which provides a more stable environment for biotech funding to show signs of recovery, signaling renewed confidence,” Jakimaviciute said. “Supply chain disruptions that plagued the pharmaceutical industry during the past few years are becoming less intense.” .

Jakimaviciute说：“尽管地缘政治形势仍面临挑战，但通货膨胀率正在逐渐下降，这为生物技术资金提供了一个更稳定的环境，以显示复苏迹象，表明人们重新树立了信心。”。“过去几年困扰制药行业的供应链中断正变得不那么严重。”。

GlobalData also assessed attitudes to the European Union’s reform of pharma legislation. While industry groups have sounded the alarm about aspects of the proposals, many of the survey respondents are upbeat, with 32% of people saying the reforms are positive for the industry. Around 20% of people see the changes as a negative, with the remaining 47% of respondents expecting a neutral impact..

GlobalData还评估了对欧盟制药立法改革的态度。虽然行业团体对这些提议的各个方面发出了警报，但许多受访者表示乐观，32%的人表示改革对行业有积极影响。大约20%的人认为这些变化是负面的，其余47%的受访者预计会产生中性影响。。